Bal Pharma Ltd
Bal Pharma Ltd Company History
Bal Pharma is engaged in the manufacturing and selling of pharmaceutical products.
2001
Bal Pharma acquires injectibles co in South African
2001
2003
The company has recommended a dividend of 12%
2003
2005
Bal Pharma wins best exporter award
The rights issue of Bal Pharma, Bangalore-based medium sized pharmaceutical company, has been oversubscribed 1.6 times. It has seen a fund generation of Rs 13.65 crore, as against the issue amount of Rs 11.75 crore. Bal Pharma issued 39.18 lakh equity shares of Rs 10 each to the existing shareholders on rights basis in the ratio of 3:5 at a price of Rs 30 per equity share, i.e. at a premium of Rs 20 per share amounting to Rs 11.75 crore.
2005
2006
The Company has obtained accreditation of Japanese Government as a foreign manufacturer for APIs and this shall certainly facilitate registration and marketing of the Company APIs in Japan.
2006
2007
The company has recommended a Dividend of Rs.7.5% per share.
2007
2008
Bal Pharma has recommended Dividend of 10%
2008
2009
Bal Pharma has recommended Dividend of Rs.0.75 per equity share of Rs.10 each.
2009
2011
Bal Pharma appointed Mr. D. Muarali as the Company Secretary & Compliance Officer of the company.
2011
2012
Bal Pharma appointed Mr. Venkatesan Murali as General Manager - Finance and Company Secretary of the Company.
2012
2013
Bal Pharma has recommended payment of dividend of Re. 0.75 (7.5%) per equity share of Rs. 10 each.
2013
2014
Bal Pharma has recommended payment of dividend of Re. 1/- (10%) per Equity Share of Rs. 10 each.
2014
2015
Bal Pharma Ltd has titled "Bal Pharma ventures into OTC Segment".
2015
2021
Bal Pharma Ltd has launched antiviral drug Favipiravir in the domestic market under the brand name BAL flu for the treatment of COVID-19.
Bal Pharma Limited has informed the Exchange about Acquisition of 650000 equity shares of the Company by Mr.Shailesh Siroya
2021
2023
NCLT given approval for merger of Golden Drugs Pvt Ltd with Bal Pharma Limited,
2023
